Alexza Pharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2001-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.alexza.com
Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT05979415
- Locations
- 🇺🇸
Cenexel Rocky Mountain Clinical Research, Englewood, Colorado, United States
🇺🇸CenExel iResearch Atlanta (Decatur), Decatur, Georgia, United States
🇺🇸Quest Research Institute, Farmington Hills, Michigan, United States
Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome
- Conditions
- Cyclic Vomiting Syndrome
- Interventions
- Combination Product: 1mg AZ010Combination Product: Staccato PlaceboCombination Product: 3mg AZ-010
- First Posted Date
- 2020-11-27
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 151
- Registration Number
- NCT04645953
- Locations
- 🇺🇸
Pioneer Research Solutions, Houston, Texas, United States
🇺🇸Om Research, Lancaster, California, United States
🇺🇸Summit Clinical Studies, Athens, Georgia, United States
Staccato® Granisetron Multiple Dose PK
- Conditions
- Healthy
- Interventions
- Combination Product: 0.5mg AZ-010Combination Product: 3mg AZ-010Combination Product: 1mg AZ-010
- First Posted Date
- 2020-03-31
- Last Posted Date
- 2020-10-30
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT04327765
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Staccato® Granisetron Single Dose PK
- Conditions
- Healthy
- Interventions
- Combination Product: 0.5mg AZ-010; placeboCombination Product: 3mg AZ-010Combination Product: AZ-010 1mgCombination Product: 1mg AZ-010Other: PlaceboDrug: IV Granisetron 1mg
- First Posted Date
- 2019-12-16
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04200092
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Staccato Apomorphine Multi-dose PK and PD in Patients With Parkinson's Disease
- Conditions
- Parkinson's Disease
- Interventions
- Drug: 009-A2Drug: 009-A0Drug: 009-B2 (placebo --> active) crossoverDrug: 009-A1Drug: 009-A3Drug: 009-B1 (active --> placebo) crossover
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2020-11-04
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT04157933
- Locations
- 🇳🇱
Centre for Human Drug Research, Leiden, Netherlands
Staccato Apomorphine Single and Multi Dose PK
- Conditions
- Parkinson Disease
- Interventions
- Drug: 009-0Drug: 009-3Drug: 009-1Drug: 009-4Drug: 009-2Drug: 009-5Drug: active comparator
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2019-08-30
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT03822364
- Locations
- 🇳🇱
Center for Human Drug Research, Leiden, Netherlands
Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder
- Conditions
- Agitation,Psychomotor
- Interventions
- First Posted Date
- 2018-05-01
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 10000
- Registration Number
- NCT03513549
- Locations
- 🇺🇸
Pharmaceutical Research Associates, Inc, Raleigh, North Carolina, United States
Staccato Alprazolam and Photoparoxysmal Response
- Conditions
- Epilepsy
- Interventions
- Drug: A=PlaceboDrug: E=Placebo
- First Posted Date
- 2015-01-30
- Last Posted Date
- 2021-08-10
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT02351115
- Locations
- 🇺🇸
New York University Epilepsy Center, New York, New York, United States
🇺🇸Consultants in Epilepsy & Neurology, PLLC, Boise, Idaho, United States
🇺🇸University of Pennsylvania - Penn Epilepsy Center, Philadelphia, Pennsylvania, United States
ADASUVE-Lorazepam Drug-Drug Interaction
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2013-06-14
- Last Posted Date
- 2017-12-13
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT01877642
- Locations
- 🇺🇸
Covance-Evansville, Evansville, Indiana, United States
ADASUVE 2-dose Thorough QT/QTc Study
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Inhaled PlaceboDrug: Oral placebo
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2017-10-18
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT01854710
- Locations
- 🇳🇱
PRA International, Zuidlaren, Netherlands